Comparative Safety and Effectiveness of Denosumab Versus Zoledronic Acid in Patients With Osteoporosis: A Cohort Study
Comparative Safety and Effectiveness of Denosumab Versus Zoledronic Acid in Patients With Osteoporosis: A Cohort Study
复制标题
DOI：
10.1002/jbmr.3019
复制
发表时间：
2017-03-01
影响因子：
6.2
通讯作者：
Kim, Seoyoung C.
中科院分区：
文献类型：
--
作者：
Choi, Nam-Kyong;Solomon, Daniel H.;Kim, Seoyoung C.
在现实世界的医疗保健中，Denosumab和唑来膦酸之间的头对头比较安全性和有效性数据有限。我们的目的是检查地舒单抗与唑来膦酸相比，在严重感染和心血管疾病（CVD）和骨质疏松性骨折风险方面的安全性和有效性。我们使用来自美国商业保险计划数据库的索赔数据（2009-2013）进行了一项队列研究。我们纳入了年龄≥ 50岁的新开始使用地舒单抗或唑来膦酸的患者。主要结局为（1）因严重感染住院;（2）复合CVD终点，包括心肌梗死、卒中、冠状动脉血运重建和心力衰竭;（3）非椎骨骨折，包括髋关节、腕关节、前臂和骨盆骨折。为了控制潜在的混杂因素，我们使用1：1倾向评分（PS）匹配。考克斯比例风险模型比较了地舒单抗与唑来膦酸治疗开始后365天内严重感染、CVD和骨质疏松性骨折的风险。PS匹配后，共选择了2467对地舒单抗和唑来膦酸启动剂，平均年龄为63岁，96%为女性。与唑来膦酸相比，地舒单抗与严重感染（HR 0.81; 95%置信区间[CI]，0.55 - 1.21）或CVD（HR 1.11; 95% CI，0.60 - 2.03）风险增加无关。对于CVD的每个组分获得了类似的结果。两组间的腰椎骨折风险也相似（HR 1.21; 95% CI，0.84 - 1.73）。这项基于人群的大规模队列研究表明，在开始用药后365天内，地舒单抗和唑来膦酸在严重感染、心血管疾病和骨质疏松骨折的风险方面具有相当的临床安全性和有效性。(C)2016年美国骨与矿物质研究学会。
Limited head-to-head comparative safety and effectiveness data exist between denosumab and zoledronic acid in real-world healthcare. We aimed to examine the safety and effectiveness of denosumab compared to zoledronic acid with regard to risk of serious infection and cardiovascular disease (CVD) and osteoporotic fracture. We conducted a cohort study using claims data (2009-2013) from a US commercial insurance plan database. We included patients aged >= 50 years who were newly initiated on denosumab or zoledronic acid. The primary outcomes were (1) hospitalization for serious infection; (2) composite CVD endpoint including myocardial infarction, stroke, coronary revascularization, and heart failure; and (3) nonvertebral osteoporotic fracture including hip, wrist, forearm, and pelvic fracture. To control for potential confounders, we used 1: 1 propensity score (PS) matching. Cox proportional hazards models compared the risk of serious infection, CVD, and osteoporotic fracture within 365 days after initiation of denosumab versus zoledronic acid. After PS matching, a total of 2467 pairs of denosumab and zoledronic acid initiators were selected with a mean age of 63 years and 96% were female. When compared with zoledronic acid, denosumab was not associated with an increased risk of serious infection (HR 0.81; 95% confidence interval [CI], 0.55 to 1.21) or CVD (HR 1.11; 95% CI, 0.60 to 2.03). Similar results were obtained for each component of CVD. The risk of osteoporotic fracture was also similar between groups (HR 1.21; 95% CI, 0.84 to 1.73). This large population-based cohort study shows that denosumab and zoledronic acid have comparable clinical safety and effectiveness with regard to the risk of serious infection, CVD, and osteoporosis fracture within 365 days after initiation of medications. (C) 2016 American Society for Bone and Mineral Research.